Giving a neuromuscular blocking agent early in ARDS may improve survival

According to a study in the New England Journal of Medicine, administering a neuromuscular blocking agent for 48 hours at the onset of severe Adult Respiratory Distress Syndrome (ARDS) improved patient survival at 90 days without worsening muscle weakness. Read more here.

LEAVE A REPLY

Please enter your comment!
Please enter your name here